DAILYPEPTIDE GUIDE
Unstandardized combination

SS-31 + MOTS-c

Elamipretide + MOTS-c

Uncertain or Concerning

Video guide

Video guides are coming soon.

Identity

Commercial or common name

SS-31 + MOTS-c. This name is not standardized.

Variants

Reported formulation variants

  • Co-administration and mixed-vial claims
Combination evidence

What the combination shows

No adequate human combination evidence was identified in the static MVP review. Component-level findings do not transfer to the combination.

Regulatory

Status

Unapproved / RUO. No approval is implied by use of a commercial or community name.

Human research

Combination trial status

No validated human combination trial identified

Quality

Stability and compatibility

Compatibility, sterility and stability are not established across marketed variants

Claims

Common marketing claims

  • Mitochondrial support
  • Energy and longevity
Evidence-based conclusion

Bottom line

This named stack should be evaluated as an unstandardized combination. It does not inherit the evidence score of its strongest component.

Individual component evidence

Approved Therapeutic2025-09-19

Elamipretide

SS-31

SS-31 is the research name commonly associated with elamipretide, the ingredient in Forzinity.

Human trials · see profileApproved
Experimental / RUOVerification pending

MOTS-c

Mitochondrial open reading frame of 12S rRNA-c

A mitochondria-derived peptide studied in metabolism and exercise-related research.

Tier 3Unapproved / RUO